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DObjectives: Various lesion sets and subsequent success rates have been reported in patients receiving concom-
itant surgical ablation for atrial fibrillation. However, most of these results have been obtained by discontinuous
monitoring. We report results using continuous event recorder rhythm monitoring to compare more accurately
the efficacy of a left versus biatrial lesion set to treat patients with persistent atrial fibrillation.
Methods: Between July 2008 and December 2011, 66 patients with persistent or long-standing persistent atrial
fibrillation underwent concomitant surgical atrial fibrillation ablation with a biatrial lesion set and subcutaneous
event recorder implantation. The results and outcomes were compared with a propensity score–matched cohort
of 66 patients with a left atrial lesion set and event recorder implantation. Event recorder interrogation was
performed at 3, 6, and 12 months follow-up.
Results: The mean patient age was 70.2  7.4 years, and 70.3% were male. No major ablation-related compli-
cations occurred. One-year survival was 94.8% with no statistically significant differences between the 2
groups. The overall rate of freedom from atrial fibrillation was 57.3% and 64.4% after 3 and 12 months
follow-up, respectively. Three months postoperatively, patients in the biatrial group had a slightly higher rate
of freedom from atrial fibrillation (63.6% vs 52.3% P ¼ .22), but it did not reach statistical significance. At
12 months follow-up, a statistically significant higher rate of freedom from atrial fibrillation was observed in
patients with a biatrial lesion set (74.4% vs 55.8%; P¼ .026). The mean atrial fibrillation burden in all patients
was 15.1% 12.5% in the biatrial group and 21.2% 14.4% in the left atrial group 12 months postoperatively
(P ¼ .03).
Conclusions: Continuous rhythm monitoring by subcutaneous event recorder implantation was safe and
feasible. In patients undergoing biatrial ablation, a statistically significant higher rate of freedom from atrial
fibrillation was observed at 12 months follow-up. (J Thorac Cardiovasc Surg 2014;148:2161-6)Atrial fibrillation (AF) is associated with an increased num-
ber of thromboembolic events, including stroke. Further-
more, it can lead to heart failure and results in an
increased number of hospitalizations.1,2 Therefore,
concomitant surgical AF ablation is recommended by
guidelines for symptomatic patients and for asymptomatic
patients at low risk for the surgical ablation procedure.2,3
Cox first reported his surgical AF ablation technique
using the cut-and-sew principle in 1987, which was subse-
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The Journal of Thoracic and CarBecause of success rates greater than 90%, the Cox-Maze
III procedure became the gold standard for surgical AF abla-
tion.However, because of the complexity of the procedure, it
was performedbyonly a few surgeons.After the cut-and-sew
principlewas recently replacedwith the creation of transmu-
ral thermal lesions via the application of different energy
sources, such as radiofrequency, high-frequency ultrasound,
or cryotherapy, the use of the procedure has become wide-
spread. This procedure is known as the ‘‘Cox-Maze IV’’
and contains a similar lesion set as in the initial Cox-Maze
III procedure, including lesions in both atria.4
Different modifications and simplifications of the original
lesion set have been used over the years. Inmost patients, AF
originates at the pulmonary veins, especially in patients with
paroxysmal AF, and in such cases, a left atrial lesion set is
considered sufficient by many specialists. However, in pa-
tients with persistent or long-standing persistent AF, there
is an ongoing discussion about whether a biatrial lesion set
results in higher success rates.4-8 All of the recent
published studies comparing the efficacy of different lesion
sets used discontinuous rhythm monitoring. However,
studies comparing the efficacy of different follow-updiovascular Surgery c Volume 148, Number 5 2161
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time rhythm monitoring, even with repeated 24-hour Holter
electrocardiography (ECG), underestimates the rate of AF
recurrence.9 The Reveal XT Performance Trial (XPECT)
trial showedhigh sensitivity (96.1%) and negativepredictive
value (97.4%) for the detection ofAF episodes by theReveal
XT (Medtronic Inc, Minneapolis, Minn) device,10 a subcu-
taneous implantable event recorder (ER). This device is pro-
grammed to detect arrhythmia episodes by analysis of
irregularity and incoherence of R-R intervals. The Reveal
XT is able to detect the duration of AF episodes and burden,
defined as the percentage of time the patient is in AF during
follow-up. The aim of our study was to compare the efficacy
of left and biatrial lesion sets through continuous rhythm
monitoring using subcutaneous ER implantation.
MATERIALS AND METHODS
From July 2008 to December 2011, 255 patients underwent concomitant
surgical ablation because of persistent or long-standing persistent AF. Of
those patients, 88 received biatrial ablation and 167 received left atrial abla-
tion. Classification of persistent and long-standing persistent AF was
according to Heart Rhythm Society/European Heart Rhythm Associa-
tion/European Cardiac Arrhythmia Society expert consensus statement
on catheter and surgical ablation of AF.3 Propensity score matching
resulted in a group of 66 patients who received a biatrial lesion set and sub-
cutaneous ER (Reveal XT) implantation and a control group of 66 patients
who received a left atrial lesion set and ER implantation. All patients
received implantation of the Reveal device during surgical ablation
procedure. Patients were matched by age, gender, left ventricular ejection
fraction, left atrial diameter, AF duration, surgical procedure, and energy
source type.
In group 1, biatrial ablation was performed in 66 patients, including left
atrial bilateral pulmonary vein ablation, box lesion, and left atrial
appendage and isthmus isolation. Right sided-lesion set included an inter-
caval lesion and isolation of the cavotricuspid isthmus, right atrial
appendage, and terminal crest. In group 2, only the left atrial lesion set
was conducted. Applied energy sources included argon-based cryoablation
(cryoICE cryoablation probe, AtriCure Inc, West Chester, Ohio; Cardio-
blate CryoFlex Surgical Ablation Probe,Medtronic Inc) in 21 patients (bia-
trial, n ¼ 12; left atrial, n ¼ 9; P ¼ .63), unipolar radiofrequency ablation
(Cardioblate unipolar RF pen, Medtronic Inc) in 52 patients (biatrial,
n ¼ 28; left atrial, n ¼ 24; P ¼ .37), and bipolar ablation (Cardioblate
BP2 device and Cardioblate Surgical Ablation System Generator, Med-
tronic Inc; Atricure Isolator Synergy Ablation Clamp, AtriCure Inc) in
59 patients (biatrial, n ¼ 26; left atrial, n ¼ 33). None of these energy
sources were used in combination.
Statistical Analysis
All statistical analyses were performed using SPSS version 18.0 (SPSS
Inc, Chicago, Ill). Continuous values are expressed as mean standard de-
viation and were compared using the Student t test or Mann–Whitney test
as appropriate. Categoric variables are displayed as frequencies, and2162 The Journal of Thoracic and Cardiovascular Surpercentages were compared using the chi-square test or Fisher exact test
as appropriate. Reported P values are 2-sided. A logistic regression model
was used to generate a control group with a left atrial lesion set matched for
the variables detailed earlier. Matching was performed by selecting a pa-
tient randomly from the biatrial group and identifying a partner in the con-
trol group with the nearest logit-transformed propensity score. Matching
balance was assessed using statistical analysis with the Fisher exact test
for categoric variables and the Student t test for continuous variables.
Follow-up
Follow-up with ER interrogation was conducted 3, 6, and 12 months
postoperatively. AF recurrence was defined as an AF burden greater than
0.5% or a single stored AF episode with duration more than 30 seconds
on ER interrogation. However, one needs to realize that the Reveal ER
has a blanking period of 2 minutes because R-R intervals are analyzed
within each 2-minute period of time. When there is a uncorrelated irregu-
larity of the R-R intervals within the 2-minute interval, the heart rhythm in
this period is classified as AF. All stored episodes were manually validated
during follow-up visits. The primary end point of the study was freedom
from AF after 12 months. To obtain success rate at 12 months, stored AF
episodes from ER interrogation between 6 and 12 months were included.
The postoperative and discharge rhythm results were obtained using
12-lead ECG. The antiarrhythmic drugs and anticoagulation regimens
were maintained for 3 months postoperatively in all patients and then
adapted according to the ER rhythm results. In patients without contraindi-
cations, amiodarone was used as the first-line antiarrhythmic drug therapy;
otherwise, other class I or III antiarrhythmic drugs were used for at least 3
months postoperatively.RESULTS
Baseline patient characteristics are shown in Table 1.
Because of the matching process, there were no statistically
significant differences between the 2 groups. The mean pa-
tient age was 70.1  7.5 years in the left atrial group and
70.5 7.3 years in the biatrial group. The mean left ventric-
ular ejection fraction was 51.5% 10.9% in patients with a
left atrial lesion set and 51.9%  10.8% in the biatrial
group. The mean left atrial diameter was 53.6  7.5 mm
for patients with a left atrial lesion set and 54.9  8.0 mm
in patients with biatrial ablation. The mean AF duration
was 3.9  3.2 years in patients with a left atrial set and
4.5  3.8 years for patients with a biatrial lesion set. Surgi-
cal procedures and applied energy sources were equally
distributed between the 2 groups (Table 2).
No major ablation or ER-associated complications
occurred in any of the patients. There were no cases of intra-
operative death. The in-hospital mortality rate was 2.2%
(3/132) (biatrial, 3.0% 2/66; left atrial, 1.5% 1/66;
P ¼ .25), whereas the 30-day mortality rate was 3.0%
(4/132) (biatrial, 3.0%; left atrial, 3.0%). The 1-year sur-
vival was 94.8% (125/132), and there were no statistically
significant differences between the 2 groups (biatrial,
95.6%; left atrial, 93.9% P ¼ .68). Three of 125 patients
(2.4%) experienced perioperative stroke (left atrial, 2/63
[1.8%]; biatrial, n ¼ 1/62 [1.0%]). Postoperative new per-
manent pacemaker implantation rate was 11.2% (7/62) and
6.5% (4/63) (P ¼ .5) in the biatrial and left atrial groups,
respectively.gery c November 2014




n ¼ 66 P value
Age (y) 70.1  7.5 70.5  7.3 .64
Gender (male n,%) 40 (60.1) 45 (68.2) .46
AF duration (y) 3.9  3.2 4.5  3.8 .33
LA diameter (mm) 53.6  7.5 54.9  8.0 .27
Long-standing persistent AF, n (%) 54 (81.8) 58 (87.9) .46
Persistent AF, n (%) 12 (18.1) 8 (12.1) .47
LVEF (%) 51.5  10.9 51.9  10.8 .81
Diabetes, n (%) 13 (19.7) 16 (24.2) .67
Renal insufficiency, n (%) 7 (10.6) 5 (7.6) .76
Prior stroke, n (%) 5 (7.6) 6 (9.1) .77
COPD, n (%) 8 (12.1) 7 (10.6) 1.0
CAD, n (%) 34 (51.5) 39 (59.1) .48
AF, Atrial fibrillation; CAD, coronary artery disease; COPD, chronic obstructive
pulmonary disease; LA, left atrial; LVEF, left ventricular ejection fraction.
FIGURE 1. Sinus rhythm rates during follow-up.




All patients underwent ER interrogation at 3 and 12
months of follow-up. Six-month follow-up was performed
in 61.7% of patients (69/132). There was no statistically
significant difference between the 2 groups in terms of
freedom from AF immediately after the procedure and at
the time of discharge (left atrial 51.4% [34/66] vs
62.1% [41/66], P ¼ .28 and left atrial 51.1% [33/65] vs
60.6% [41/64], P ¼ .28, respectively) (Figure 1). At 3
and 6 months of follow-up, there were no significant dif-
ferences in freedom from AF between the left atrial and
biatrial groups (left atrial 53.2% [33/62] vs 63.9% [39/
61], P ¼ .22 and 56.3% [18/32] vs 67.3% [25/37],
P ¼ .20, respectively). However, it must be considered
that only 61.7% of the patients underwent a 6-month
follow-up.
One-year follow-up revealed a significantly different rate
of freedom from AF of 55.8% (35/63) for patients with left
atrial ablation compared with 74.4% (46/62) for patients
with a biatrial lesion set (P ¼ .026) (Figure 1). The rate
of freedom from AF at 12 months follow-up off class ITABLE 2. Surgical procedures and ablation energy sources
Left atrial n ¼ 66 Biatrial n ¼ 66 P value
CABG, n (%) 21 (31.8) 17 (25.8) .56
AVR, n (%) 10 (15.2) 7 (10.6) .60
MVR, n (%) 16 (24.2) 22 (33.3) .34
CABG þ valve 11 (16.7) 13 (19.7) .82
MVR þ TVR, n (%) 4 (6.1) 2 (3.0) .67
Other, n (%) 4 (6.1) 5 (7.6) 1.0
RF bipolar, n (%) 33 (50.0) 26 (39.4) .16
RF unipolar, n (%) 24 (36.4) 28 (42.4) .37
Cryoablation, n (%) 9 (13.6) 12 (18.2) .63
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting;MVR, mitral
valve repair or replacement; RF, radiofrequency; TVR, tricuspid valve repair.
The Journal of Thoracic and Carand III antiarrhythmic drugs was 50.7% (32/63) and
68.1% (42/66), respectively (P ¼ .033). However, freedom
from oral anticoagulation at 12 months follow-up was only
25.4% (16/63) in the biatrial group and 24.1% (15/62) in
the left atrial group.Atrial Fibrillation Burden
The mean AF burden of all patients was 25% in the bia-
trial group and 39% in the left atrial group at 3 months of
follow-up. At 12 months of follow-up, a reduced AF
burden was seen in all patients irrespective of ablation
success. The AF burden in the entire cohort was 15.1%
 12.5% (n ¼ 62) in the biatrial group and 21.3% 
14.4% (n ¼ 63) in the left atrial group 12 months postop-
eratively (P ¼ .03). For patients in whom ablation failed,
the mean AF burdens of 35% (n ¼ 62) and 43% (n ¼ 63)
were seen in the biatrial and left atrial groups,
respectively.DISCUSSION
In the literature, no consensus has been reached about
the appropriate lesion set for patients with different types
of AF. Specifically, there is a controversial discussion on
which patients should be treated with an additional
right-sided lesion set. In our study, we showed a statisti-
cally higher rate of sinus rhythm after 12 months in pa-
tients with persistent or long-standing persistent AF
treated with a biatrial lesion set. This finding is consistent
with a previous published meta-analysis by Barnett and
Ad4 that included 69 studies with an overall number of
5885 patients with AF who received cardiac surgery alone
or cardiac surgery with concomitant surgical ablation. In
their analysis, the patients who received surgical ablation
had statistically significant higher rates of sinus rhythm
at all points of follow-up to 3 years. Furthermore, patients
who had received the biatrial lesion set had statisticallydiovascular Surgery c Volume 148, Number 5 2163
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the left atrial lesion set. Similar results were shown in a
meta-analysis by Cheng and colleagues11 that included
4647 patients with persistent or long-standing persistent
AF. However, a higher incidence of postoperative perma-
nent pacemaker dependency for patients receiving biatrial
ablation has been shown in previous published studies, and
caution is recommended while performing right-sided
lesions.12,13
In contrast to the results published by Barnett and
Ad4 and Cheng and colleagues,11 other studies have
indicated no difference in rhythm results between pa-
tients who received left atrial and biatrial ablation. A
recent study by Soni and colleagues14 showed the rates
of freedom from AF in patients who underwent biatrial
lesion set, left atrial lesion set, and pulmonary vein
isolation were 80.0%, 76.1%, and 56.9%, respectively,
at 12 months of follow-up. This analysis suggested no
improvement in patients who underwent an additional
right atrial lesion set.14 The limitation of this study is
that the success rates were obtained using 12-lead
ECG, but a more extensive follow-up with at least a
24-hour Holter ECG would probably show different
results.
However, it needs to be stressed that in most of the
previous published studies, ablation success was defined
by use of 12-lead ECG or 24-hour Holter moni-
toring.4-6,12,15-17 Recent studies comparing the
accuracy of rhythm detection using different follow-up
methods after AF ablation showed that intermittent
rhythm monitoring underestimates the actual AF recur-
rence rate.9,17 Furthermore, after AF ablation, even
patients in whom ablation failed may have reduced
AF burden, which makes the detection of AF
recurrence with snapshot follow-up methods more diffi-
cult and unreliable. Our study was the first to assess
success rates of biatrial and left atrial lesion sets using
continuous subcutaneous implanted ER monitoring. We
demonstrated superior results concerning freedom from
AF recurrence in patients receiving biatrial ablation af-
ter 1 year of follow-up. The use of continuous rhythm
monitoring in our study allows for a more accurate
comparison of the 2 different lesion sets, because the
sensitivity to detect recurrent AF episodes is high
with this method. However, the ER used in this study
has a limited storage capacity of 49.5 minutes. There-
fore, in patients with a high AF burden, not all stored
episodes can be manually validated, and there is a
certain risk to over- or underestimate the AF burden.
Furthermore, the Reveal ER classifies the heart rhythm
for each subsequent time interval of 2 minutes and can
only detect AF episodes with a duration of at least 2
minutes. This means that every stored episode in the
Reveal ER corresponds to an AF duration of more2164 The Journal of Thoracic and Cardiovascular Surthan 2 minutes and represents a failure of ablation ac-
cording to the guidelines. Despite this 2-minute blank-
ing period, in previous published studies it has been
shown that the Reveal device is an excellent tool to
predict freedom from AF because of its high negative
predictive values.10 Despite these limitations, the ability
to detect AF episodes is far better than with 24-hour, 7-
day, or 30-day monitoring,9,18,19 and in our opinion, ER
monitoring is the best available monitoring strategy to
date.
An important observation in our study was the increase
in the sinus rhythm rate between 3 and 12 months follow-
up. The current study also showed a reduction of AF
burden over time, even in patients in whom ablation failed.
However, the impact of reduction in AF burden and the re-
sulting consequences remain undefined yet. Future larger,
prospective studies need to be performed to determine
clinically relevant cutoff values for the AF burden in re-
gard to the anticoagulation and antiarrhythmic drug
regimens.
Our study did not show a survival benefit for patients with
restored sinus rhythm. Furthermore, no significant differ-
ences were observed in the survivals of patients with a
left or biatrial lesion set. These results may be due to the
relatively short 12-month follow-up period and the limited
number of included patients. Regardless, this finding is
consistent with the results of the meta-analysis by Barnett
and colleagues,4 in which similar survivals were reported
for patients with and without successful ablation. In
contrast, in a propensity score–matched analysis by Lee
and colleagues,20 patients with AF receiving surgical abla-
tion had similar survival compared with patients without a
history of AF. Furthermore, they showed a survival benefit
for patients with successful ablation compared with those in
whom AF ablation failed.20 These first promising results
have to be confirmed in larger, prospective, randomized tri-
als to determine the impact of AF surgery on long-term
survival.
After 1 year of follow-up, no statistically significant dif-
ference was observed between the left and biatrial ablation
groups in regard to stroke-free survival in the current
study. This finding may be the result of low incidences
of postoperative stroke in both groups, which may be
one of the advantages of left atrial appendage closure or
excision, which can be easily done during surgical AF
ablation.
Measurement of AF burden is a relatively new method
to determine the time a patient spent in AF. If a patient has
an AF burden of 0% over a certain period of time, we
consider the ablation as successful and the patient as AF
free. Nevertheless, the impact of reduction in AF burden
and the resulting consequences remain undefined. Future
larger prospective studies need to be performed to deter-
mine clinically relevant cutoff values for the AF burdengery c November 2014




The major limitation of this study is that we used a retro-
spective data analysis to compare the biatrial and left atrial
lesion set groups. Although we minimized the differences
between the 2 groups bymatching the patients using a logis-
tic regression model, the disadvantages of a retrospective,
nonrandomized study, including unknown confounders
and selection and detection bias, cannot be completely
avoided.
Further limitations are due to technical aspects of ER
with its limited storage capacity of 49.5 minutes. There-
fore, in patients with a high AF burden, not all stored ep-
isodes can be validated manually, and there is a certain
risk to over- or underestimate AF burden. Furthermore,
the ER used in this study classifies the heart rhythm for
each subsequent time interval of 2 minutes and only de-
tects AF episodes with a duration of at least 2 minutes.
This 2-minute blanking period of the ER may result in un-
derestimation of AF episodes. Additional limitations of
the study are that we did not use intraoperative electro-
physiologic mapping and testing to confirm the quality
of the applied lesions, and that no follow-up beyond 12
months is available.
We started to perform AF surgery in 2002 and initially
used only left atrial lesions in all patients. As a result of
the published data and our own experience, in 2008 we
introduced the use of biatrial lesions in patients with persis-
tent and long-standing persistent AF. Therefore, the results
of the biatrial ablation may be influenced by a certain
learning curve.
Moreover, the heterogeneity of the energy sources used is
a limitation of the study. Furthermore, there was no consis-
tent treatment of left atrial appendage (excision or to exclu-
sion), and we did not routinely use transesophageal
echocardiography postoperatively to control the success
of left atrial appendage management.
CONCLUSIONS
In the current study, in which all rhythm results were
obtained by ERmonitoring, we showed that a biatrial lesion
set in patients with persistent AF results in statistically sig-
nificant higher sinus rhythm rates at 12 months follow-up.
Furthermore, over time, patients showed a reduction of
AF burden, even those in whom ablation failed.References
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